PHYSIOGENIX, INC.

Basic Information

PHYSIOGENIX, INC.
10437 INNOVATION DR, STE 325
WAUWATOSA, WI, 53226-4838

Company Profile

n/a

Additional Details

Field Value
DUNS: 140323531
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Efficacy of GABAA a5 receptor inverse agonists in learning impaired rats

    Amount: $343,796.00

    DESCRIPTION (provided by applicant): The number of patients in the United States afflicted with learning and memory disorders is rapidly increasing. This necessitates the development of new, better a ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Consomic rat panels for pharmacogenomic studies and target identification

    Amount: $1,376,163.00

    Not avaiable.

    SBIR Phase II 2007 Department of Health and Human Services
  3. Consomic rat panels for pharmacogenomic studies and target identification

    Amount: $1,644,226.00

    DESCRIPTION (provided by applicant): PhysioGenix plans to commercialize a rat discovery platform that markedly accelerates the deployment of genetic tools for drug development by Pharma. While genetic ...

    SBIR Phase I 2006 Department of Health and Human Services
  4. Molecular fingerprints of alcohol-induced organ damage using new genetic models

    Amount: $251,239.00

    DESCRIPTION (provided by applicant): This SBIR project combines the use of genetic models with genomic, proteomic and metabolomic technologies as a solution to discover molecular fingerprints as bioma ...

    SBIR Phase I 2006 Department of Health and Human Services
  5. Combinatorial rat panels for pharmacogenetic effects

    Amount: $134,425.00

    DESCRIPTION (provided by applicant): The concept of a pre-clinical, drug screen for genetic effects was developed by PhysioGenix in Phase I of this project. The screen consists of inbred rats bred in ...

    SBIR Phase II 2004 Department of Health and Human Services
  6. Identifying drug toxicity signatures using QCarrays

    Amount: $498,610.00

    DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity ...

    SBIR Phase I 2004 Department of Health and Human Services
  7. Combinatorial rat panels that genetically screen anthrax

    Amount: $312,536.00

    DESCRIPTION (provided by applicant): The recent anthrax-related events have revealed the need to fill gaps in the knowledge base that compromise our response to a bioterrorist attack using Category A ...

    SBIR Phase I 2003 Department of Health and Human Services
  8. DESIGNER RAT MODELS THAT MIMIC TYPE 2 DIABETES

    Amount: $489,659.00

    This SBIR Phase I project will employ a new bioinformatic tool to combine in silico gene mapping and comparative genomics for predicting designer rat strains that mimic human disease. The genome sequ ...

    SBIR Phase I 2002 Department of Health and Human Services
  9. COMBINATORIAL RAT PANELS FOR PHARMACOGENETIC EFFECTS

    Amount: $100,000.00

    This SBIR Phase I project will create and validate a combinatorial panel of rats designed to detect genetic differences to drug response including toxicity. The genome sequencing projects are bringing ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government